Q2 2024 Matinas BioPharma Holdings Inc Earnings Call Transcript
Key Points
- Matinas BioPharma Holdings Inc (MTNB) has signed a nonbinding term sheet for the global licensing of MAT2203, indicating progress in their partnership efforts.
- The compassionate expanded use access program for MAT2203 has shown positive clinical outcomes in critically ill patients, bolstering confidence in the drug's efficacy and safety.
- Recent studies have demonstrated the potential of the LNC platform in delivering small oligonucleotides and small-molecule oncology drugs, showing promise in tumor growth inhibition.
- The company has reported a decrease in net loss and total expenses for the second quarter of 2024 compared to the same period in 2023, reflecting improved financial management.
- Cash, cash equivalents, and marketable securities increased to $14.3 million as of June 30, 2024, due to successful fundraising efforts, providing a stronger financial position.
- The partnership agreement for MAT2203 is still nonbinding, and there is no guarantee it will result in a definitive agreement, creating uncertainty.
- The company reported no revenue for the second quarter of 2024, similar to the same period in 2023, indicating a lack of income generation from operations.
- The anticipated start of the ORALTO Phase 3 trial for MAT2203 has been delayed, with the first patient visit now expected in early 2025, potentially impacting timelines.
- Weight loss observed in animal studies with the LNC platform, particularly with highly toxic agents like miriplatin, raises concerns about the safety and tolerability of these formulations.
- The company continues to face significant time and additional work ahead to identify additional potential product candidates from the LNC platform, indicating ongoing challenges in development.
Welcome to the Matinas BioPharma second-quarter 2024 financial results conference call. (Operator instructions) As a reminder, this conference is being recorded. I would now like to turn the conference over to Jody Cain. Please go ahead.
This is Jody Cain with LHA. Thank you for participating in today's call. Joining me from Matinas BioPharma are Jerome Jabbour, Chief Executive Officer, and Keith Kucinski, Chief Financial Officer; Dr. Theresa Matkovits, Chief Development Officer, and Dr. Terry Ferguson, Chief Medical Officer, will be available during the question and answer session.
I'd like to remind listeners that remarks made during this call may state management's future intentions hopes, beliefs, expectations or projections. These are forward-looking statements that involve risks and uncertainties. Forward-looking statements made pursuant to the safe harbor provisions of federal securities laws.
These forward-looking statements are based on current expectations and actual results
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
